JP2009508822A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009508822A5 JP2009508822A5 JP2008530342A JP2008530342A JP2009508822A5 JP 2009508822 A5 JP2009508822 A5 JP 2009508822A5 JP 2008530342 A JP2008530342 A JP 2008530342A JP 2008530342 A JP2008530342 A JP 2008530342A JP 2009508822 A5 JP2009508822 A5 JP 2009508822A5
- Authority
- JP
- Japan
- Prior art keywords
- factor
- functional
- functional factor
- plasma
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000016550 Complement Factor H Human genes 0.000 claims 22
- 108010053085 Complement Factor H Proteins 0.000 claims 22
- 238000000034 method Methods 0.000 claims 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 8
- 230000001684 chronic effect Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 201000001474 proteinuria Diseases 0.000 claims 4
- 239000000543 intermediate Substances 0.000 claims 3
- 239000002244 precipitate Substances 0.000 claims 3
- 238000001556 precipitation Methods 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- 208000037999 tubulointerstitial fibrosis Diseases 0.000 claims 2
- 102000004411 Antithrombin III Human genes 0.000 claims 1
- 108090000935 Antithrombin III Proteins 0.000 claims 1
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims 1
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims 1
- 229960005348 antithrombin iii Drugs 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 239000003480 eluent Substances 0.000 claims 1
- 230000007849 functional defect Effects 0.000 claims 1
- 239000012678 infectious agent Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 208000011511 primary membranoproliferative glomerulonephritis Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05020409 | 2005-09-19 | ||
| PCT/EP2006/005631 WO2007038995A1 (en) | 2005-09-19 | 2006-06-13 | Factor h for the treatment of chronic nephropathies and production thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012116143A Division JP2012184251A (ja) | 2005-09-19 | 2012-05-22 | 尿細管間質性線維症または進行性腎不全を処置するための機能性ｈ因子の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009508822A JP2009508822A (ja) | 2009-03-05 |
| JP2009508822A5 true JP2009508822A5 (enExample) | 2009-06-25 |
Family
ID=36001069
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008530342A Pending JP2009508822A (ja) | 2005-09-19 | 2006-06-13 | 慢性腎症の処置のためのｈ因子およびその製造 |
| JP2012116143A Pending JP2012184251A (ja) | 2005-09-19 | 2012-05-22 | 尿細管間質性線維症または進行性腎不全を処置するための機能性ｈ因子の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012116143A Pending JP2012184251A (ja) | 2005-09-19 | 2012-05-22 | 尿細管間質性線維症または進行性腎不全を処置するための機能性ｈ因子の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20090118163A1 (enExample) |
| EP (1) | EP1928483B1 (enExample) |
| JP (2) | JP2009508822A (enExample) |
| KR (1) | KR20080048034A (enExample) |
| AU (1) | AU2006299293B2 (enExample) |
| CA (1) | CA2627264A1 (enExample) |
| WO (1) | WO2007038995A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2894145B1 (fr) * | 2005-12-07 | 2008-10-17 | Lab Francais Du Fractionnement | Utilisation de facteur h du complement a titre de medicament |
| EP2129686B1 (en) * | 2007-03-20 | 2016-07-13 | CSL Behring GmbH | Methods for industrial scale production of therapeutic complement factor h preparations from human plasma |
| CN109045296A (zh) * | 2008-11-10 | 2018-12-21 | 阿雷克森制药公司 | 用于治疗补体相关障碍的方法和组合物 |
| GB0904427D0 (en) | 2009-03-13 | 2009-04-29 | Lachmann Peter | Treatment of diseases related to hyperactivity of the complement system |
| AT514675B1 (de) * | 2009-07-23 | 2019-05-15 | Baxalta Inc | Herstellung von faktor h (fh) und fh-derivaten aus plasma |
| FR2952539B1 (fr) | 2009-11-16 | 2012-01-13 | Lab Francais Du Fractionnement | Preparation d'un concentre de facteur h |
| FR2952640B1 (fr) | 2009-11-16 | 2012-12-07 | Lab Francais Du Fractionnement | Procede de fabrication d'une preparation de facteur h |
| GB0922659D0 (en) | 2009-12-24 | 2010-02-10 | Univ Edinburgh | Factor H |
| AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
| US8796430B2 (en) | 2010-05-26 | 2014-08-05 | Baxter International Inc. | Method to produce an immunoglobulin preparation with improved yield |
| WO2011150284A2 (en) | 2010-05-26 | 2011-12-01 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
| AU2011301996A1 (en) | 2010-09-15 | 2013-03-21 | Celldex Therapeutics, Inc. | Treatment of chronic nephropathies using soluble complement receptor type I (sCR1) |
| CA2812643A1 (en) * | 2010-10-13 | 2012-04-19 | Octapharma Ag | Method for purification of complement factor h |
| FR2981661B1 (fr) * | 2011-10-25 | 2015-06-19 | Lfb Biotechnologies | Procede de preparation du facteur h humain |
| FR2983212A1 (fr) | 2011-11-28 | 2013-05-31 | Lfb Biotechnologies | Aptameres anti-fh, procede pour leur obtention et utilisations |
| AU2013202965B2 (en) | 2013-03-15 | 2016-07-21 | Takeda Pharmaceutical Company Limited | Improved method for producing factor h from a plasma precipitation fraction |
| AU2013203048A1 (en) | 2013-03-15 | 2014-10-02 | Baxalta GmbH | Isolation of factor h from fraction i paste |
| KR102192596B1 (ko) | 2013-08-07 | 2020-12-18 | 알렉시온 파마슈티칼스, 인코포레이티드 | 비정형적 용혈성 요독증후군 (ahus) 바이오마커 단백질 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0742235B2 (ja) * | 1985-11-08 | 1995-05-10 | 三共株式会社 | 自己免疫性疾病の予防・治療剤 |
| US6492325B1 (en) * | 1998-05-22 | 2002-12-10 | Boys Town National Research Hospital | Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease |
| FR2894145B1 (fr) | 2005-12-07 | 2008-10-17 | Lab Francais Du Fractionnement | Utilisation de facteur h du complement a titre de medicament |
-
2006
- 2006-06-13 WO PCT/EP2006/005631 patent/WO2007038995A1/en not_active Ceased
- 2006-06-13 CA CA002627264A patent/CA2627264A1/en not_active Abandoned
- 2006-06-13 EP EP06754313.2A patent/EP1928483B1/en not_active Not-in-force
- 2006-06-13 US US11/992,194 patent/US20090118163A1/en not_active Abandoned
- 2006-06-13 JP JP2008530342A patent/JP2009508822A/ja active Pending
- 2006-06-13 KR KR1020087006719A patent/KR20080048034A/ko not_active Ceased
- 2006-06-13 AU AU2006299293A patent/AU2006299293B2/en not_active Ceased
-
2010
- 2010-11-01 US US12/916,807 patent/US10137165B2/en active Active
-
2012
- 2012-05-22 JP JP2012116143A patent/JP2012184251A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009508822A5 (enExample) | ||
| JP2014506321A5 (enExample) | ||
| MY199017A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy | |
| Bellomoc | ‘Super high-flux’or’high cut-off’hemofiltration and hemodialysis | |
| WO2008064321A3 (en) | Methods of treating chronic inflammatory diseases using a gm-csf antagonist | |
| MY178654A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy | |
| JP2008538564A5 (enExample) | ||
| DK1845994T3 (da) | Kombination af methylxanthinforbindelser og steroider til at behandle kroniske luftvejssygdomme | |
| WO2008050329A3 (en) | Novel sirnas and methods of use thereof | |
| JP2011126917A5 (enExample) | ||
| MX2010004494A (es) | Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios. | |
| WO2009045356A3 (en) | Microrna compositions in the treatment of vegf-mediated disorders | |
| JP2013521303A5 (enExample) | ||
| RU2014105513A (ru) | Противофиброзные пептиды и их применение в способах лечения заболеваний и расстройств, характеризующихся фиброзом | |
| EA201101643A1 (ru) | ВАРИАНТЫ ПРИМЕНЕНИЯ IL-1β АНТИТЕЛ И ИХ СВЯЗЫВАЮЩИХ ФРАГМЕНТОВ В СЕРДЕЧНО-СОСУДИСТОЙ СИСТЕМЕ | |
| US20180185446A1 (en) | Composition and method for inducing anti-apoptosis, survival or proliferation of a cell | |
| Habas et al. | Common complications of hemodialysis: a clinical review | |
| NO20074084L (no) | Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikamenter og medikamenter inneholdende disse | |
| JP2012502103A5 (enExample) | ||
| NZ603602A (en) | Compositions and methods for treatment of kidney disorders | |
| JP2015522603A5 (enExample) | ||
| JP2013528649A5 (enExample) | ||
| CN110114081A (zh) | 一种改善心脏病变的方法 | |
| JP2014513121A5 (enExample) | ||
| JP2013525310A5 (enExample) |